SEC Info - Therapy Cells Inc - ‘10-K’ for 12/31/11

SEC Info℠

Home

Help

Please Sign In

Therapy Cells Inc – ‘10-K’ for 12/31/11 – ‘EX-31.1’

On: Friday, 10/11/19, at 5:02pm ET · For: 12/31/11 · Accession #: 1683168-19-3240 · File #: 333-149978

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/11/19  Therapy Cells Inc                 10-K       12/31/11    3:367K                                   GlobalOne Filings Inc/FA

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    231K 
 2: EX-31.1     Certification of Chief Financial Officer            HTML     10K 
 3: EX-32.1     Certification of Chief Executive Officer and Chief  HTML      6K 
                Financial Officer

‘EX-31.1’ — Certification of Chief Financial Officer

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 31.1

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECURITIES EXCHANGE ACT OF 1934

RULE 13A-14(a) or 15D-14(a)

I, Paul Knudson, Chief Financial Officer and Principal Accounting Officer, certify that:

I have reviewed this Form 10-K for Diamond Information Institute Inc.;

Based on my knowledge of the filing history, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge of the filing history, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s certifying officer for the time period of this filing was responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter ( the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting’ and

The registrant’s certifying officer for the time period of this filing was responsible for disclosing, based on his most recent evaluation of internal control over financial reporting, to the registrant’s board of directors (or persons performing the equivalent functions);

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Therapy Cells, Inc., fka Diamond Information Institute, Inc.

Date: October 11, 2019	By: /s/ *Paul Knudson*
	Name: Paul Knudson
	Title: Chief Financial Officer (CFO)
	Principal Accounting Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	10/11/19	10-Q
For Period end:	12/31/11
		List all Filings

↑Top

Filing Submission 0001683168-19-003240 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)